DigestRedComo funciona
Red
/
Empresas
No
No verificado

Novo Nordisk A/S

Sobre qué escribimos

FarmacéuticaFinanzasGestión empresarial/Administración de EmpresasPolítica InternacionalPublicidad/Marketing/Medios de comunicación/Comunicación

90 Comunicados de prensa

Ver todos los comunicados de prensa
28/04/2026
Farmacéutica
Medicina Salud Bienestar
Publicidad/Marketing/Medios de comunicación/Comunicación
Novo Nordisk to present new data on Wegovy®, women with obesity and next-generation weight loss treatments at European Congress on Obesity
Fuente
Novo Nordisk A/S
Editor
GLOBENEWSWIRE
1.00
0
23/04/2026
Farmacéutica
Publicidad/Marketing/Medios de comunicación/Comunicación
Novo Nordisk’s oral semaglutide demonstrates potential to be the first oral GLP-1 RA therapy for children and adolescents with type 2 diabetes
Fuente
Novo Nordisk A/S
Editor
GLOBENEWSWIRE
1.00
0
20/04/2026
Farmacéutica
Política Internacional
Novo Nordisk: Etavopivat is the first in a new class of drugs to meet both co-primary endpoints in the phase 3 HIBISCUS trial, substantially reducing vaso-occlusive crisis events and improving haemoglobin response in sickle cell disease
Fuente
Novo Nordisk A/S
Editor
GLOBENEWSWIRE
1.00
0
13/04/2026
Farmacéutica
Gestión empresarial/Administración de Empresas
Novo Nordisk and OpenAI partner to transform how medicines are discovered and delivered
Fuente
Novo Nordisk A/S
Editor
GLOBENEWSWIRE
1.00
0
09/04/2026
Farmacéutica
Publicidad/Marketing/Medios de comunicación/Comunicación
Novo Nordisk A/S: Wegovy® injection becomes first GLP-1 weight-loss treatment approved for 48-hour controlled-temperature delivery in the EU
Fuente
Novo Nordisk A/S
Editor
GLOBENEWSWIRE
1.00
0
26/03/2026
Farmacéutica
Política Internacional
Novo Nordisk A/S: Awiqli® approved in the US, the first and only once-weekly basal insulin treatment for adults with type 2 diabetes
Fuente
Novo Nordisk A/S
Editor
GLOBENEWSWIRE
1.00
0
26/03/2026
Farmacéutica
Política Internacional
Resolutions from the Annual General Meeting of Novo Nordisk A/S
Fuente
Novo Nordisk A/S
Editor
GLOBENEWSWIRE
1.00
0
24/03/2026
Farmacéutica
Gestión empresarial/Administración de Empresas
Novo Nordisk A/S: Triple agonist UBT251 showed a mean HbA1c reduction of up to 2.16% after 24 weeks in phase 2 trial in Chinese patients with type 2 diabetes
Fuente
Novo Nordisk A/S
Editor
GLOBENEWSWIRE
1.00
0
19/03/2026
Farmacéutica
Política Internacional
Novo Nordisk A/S: Wegovy® HD (semaglutide 7.2 mg) approved in the US, providing 20.7% mean weight loss
Fuente
Novo Nordisk A/S
Editor
GLOBENEWSWIRE
1.00
0
02/03/2026
Farmacéutica
Política Internacional
Election of employee representatives to the Board of Directors of Novo Nordisk A/S
Fuente
Novo Nordisk A/S
Editor
GLOBENEWSWIRE
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0